However, pembrolizumab, nivolumab, and atezolizumab failed to provide survival benefits to patients with EGFR-mutated NSCLC compared with docetaxel in their respective clinical trials (1, 2, 5). This evidence concerns the gene EGFR and non-small cell lung carcinoma.